Incorporating Patient-reported Outcome Measures (PROMs) into a Clinical Quality Registry (CQR) for Ovarian Cancer: Considerations and Challenges

Overview

Journal BMC Health Serv Res

Publisher Biomed Central

Specialty Health Services

Date 2024 Jul 8

PMID 38978033

Authors

Yael R Lefkovits

Natalie Heriot

Alice Sporik

Sharnel Perera

Michael Friedlander

Cyril Dixon

Paul A Cohen

Yeh Chen Lee

Simon Hyde

Gary Richardson

Penelope Webb

Robert Rome

Madeleine King

John Zalcberg

Penelope Schofield

Affiliations

Soon will be listed here.

Abstract

As medical treatment increasingly focuses on improving health-related quality of life, patient-reported outcome measures (PROMs) are an essential component of clinical research. The National Gynae-Oncology Registry (NGOR) is an Australian clinical quality registry. A suitable PROM was required for the NGOR ovarian cancer module to complement clinical outcomes and provide insights into outcomes important to patients. Our narrative review aimed to identify existing ovarian cancer-specific PROMs and ascertain which tool would be most appropriate for implementation into the NGOR ovarian cancer module.A literature review of Cochrane Library, Embase, MEDLINE and PubMed databases was performed to identify existing ovarian cancer-specific PROM tools. A steering committee was convened to (1) determine the purpose of, and criteria for our required PROM; and (2) to review the available tools against the criteria and recommend the most appropriate one for implementation within the NGOR.The literature review yielded five tools: MOST, EORTC QLQ-OV28, FACIT-O, NFOSI-18 and QOL-OVCA. All were developed and validated for use in clinical trials, but none had been validated for use in clinical quality registry. Our expert steering committee pre-determined purpose of a PROM tool for use within the NGOR was to enable cross-service comparison and benchmarking to drive quality improvements. They identified that while there was no ideal, pre-existing, ovarian cancer-specific PROM tool for implementation into the NGOR, on the basis of its psychometric properties, its available translations, its length and its ability to be adapted, the EORTC tool is most fit-for-purpose for integration into the NGOR.This process enabled identification of the tool most appropriate to provide insights into how ovarian cancer treatments impact patients' quality of life and permit benchmarking across health services.

Citing Articles

Successful laparoscopic cytoreductive surgery for multiple (three) advanced recurrences of AGCT in a young woman. A case report.

Maccio A, Vallerino V, Sole G, Nemolato S, Giglio E, Madeddu C Int J Surg Case Rep. 2025; 127:110960.

PMID: 39874807 PMC: 11808675. DOI: 10.1016/j.ijscr.2025.110960.

References

Basen-Engquist K, Fitzgerald M, Webster K, Cella D, Hu S, Gershenson D . Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol. 2001; 19(6):1809-17. DOI: 10.1200/JCO.2001.19.6.1809. View

Redman C, Duffy S, Bromham N, Francis K . Recognition and initial management of ovarian cancer: summary of NICE guidance. BMJ. 2011; 342:d2073. DOI: 10.1136/bmj.d2073. View

Danek E, Earnest A, Wischer N, Andrikopoulos S, Pease A, Nanayakkara N . Risk-adjustment of diabetes health outcomes improves the accuracy of performance benchmarking. Sci Rep. 2018; 8(1):10261. PMC: 6035186. DOI: 10.1038/s41598-018-28101-w. View

Staniszewska S, Haywood K, Brett J, Tutton L . Patient and public involvement in patient-reported outcome measures: evolution not revolution. Patient. 2012; 5(2):79-87. DOI: 10.2165/11597150-000000000-00000. View

Luckett T, King M, Butow P, Friedlander M, Paris T . Assessing health-related quality of life in gynecologic oncology: a systematic review of questionnaires and their ability to detect clinically important differences and change. Int J Gynecol Cancer. 2010; 20(4):664-84. DOI: 10.1111/IGC.0b013e3181dad379. View

Zanotto B, Beck da Silva Etges A, Zago Marcolino M, Polanczyk C . Value-Based Healthcare Initiatives in Practice: A Systematic Review. J Healthc Manag. 2021; 66(5):340-365. PMC: 8423138. DOI: 10.1097/JHM-D-20-00283. View

King M, Stockler M, Butow P, OConnell R, Voysey M, Oza A . Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer. Int J Gynecol Cancer. 2014; 24(5):865-73. DOI: 10.1097/IGC.0000000000000167. View

Ishaque S, Karnon J, Chen G, Nair R, Salter A . A systematic review of randomised controlled trials evaluating the use of patient-reported outcome measures (PROMs). Qual Life Res. 2018; 28(3):567-592. DOI: 10.1007/s11136-018-2016-z. View

Di Maio M, Basch E, Denis F, Fallowfield L, Ganz P, Howell D . The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline. Ann Oncol. 2022; 33(9):878-892. DOI: 10.1016/j.annonc.2022.04.007. View

10.

Badia X, Herdman M . The importance of health-related quality-of-life data in determining the value of drug therapy. Clin Ther. 2001; 23(1):168-75. DOI: 10.1016/s0149-2918(01)80039-4. View

11.

Campbell R, King M, Ross T, Cohen P, Friedlander M, Webb P . Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment. Gynecol Oncol. 2021; 163(2):398-407. DOI: 10.1016/j.ygyno.2021.08.022. View

12.

Ferrell B, Cullinane C, Ervine K, Melancon C, Uman G, Juarez G . Perspectives on the impact of ovarian cancer: women's views of quality of life. Oncol Nurs Forum. 2005; 32(6):1143-9. DOI: 10.1188/05.onf.1143-1149. View

13.

Armstrong D, Alvarez R, Bakkum-Gamez J, Barroilhet L, Behbakht K, Berchuck A . NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. J Natl Compr Canc Netw. 2019; 17(8):896-909. DOI: 10.6004/jnccn.2019.0039. View

14.

Valderas J, Alonso J . Patient reported outcome measures: a model-based classification system for research and clinical practice. Qual Life Res. 2008; 17(9):1125-35. DOI: 10.1007/s11136-008-9396-4. View

15.

Preston N, Wilson N, Wood N, Brine J, Ferreira J, Brearley S . Patient-reported outcome measures for use in gynaecological oncology: a systematic review. BJOG. 2015; 122(5):615-22. DOI: 10.1111/1471-0528.13251. View

16.

Price C, de C Williams A, Smith B, Bottle A . Implementation of Patient-Reported Outcomes (PROMs) from specialist pain clinics in England and Wales: Experience from a nationwide study. Eur J Pain. 2019; 23(7):1368-1377. DOI: 10.1002/ejp.1406. View

17.

Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N . The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5):365-76. DOI: 10.1093/jnci/85.5.365. View

18.

Kurzrock R, Colevas A, Olszanski A, Akerley W, Arteaga C, Carson 3rd W . NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. J Natl Compr Canc Netw. 2015; 13(11):1337-46. DOI: 10.6004/jnccn.2015.0163. View

19.

King M, Stockler M, OConnell R, Buizen L, Joly F, Lanceley A . Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. Qual Life Res. 2017; 27(1):59-74. DOI: 10.1007/s11136-017-1729-8. View

20.

Ruseckaite R, Maharaj A, Dean J, Krysinska K, Ackerman I, Brennan A . Preliminary development of recommendations for the inclusion of patient-reported outcome measures in clinical quality registries. BMC Health Serv Res. 2022; 22(1):276. PMC: 8886855. DOI: 10.1186/s12913-022-07657-4. View